These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 23731387

  • 21. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y, Fortún J, Len Ó, Aguado JM, Moreno A, Cisneros JM, Gurguí M, Carratalà J, Muñoz P, Montejo M, Blanes M, Bou G, Pérez JL, Torre-Cisneros J, Ramos A, Pahissa A, Gavaldà J, Spanish Network for Research on Infection in Transplantation (RESITRA) and the Spanish Network for Research on Infectious Diseases (REIPI).
    Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
    [Abstract] [Full Text] [Related]

  • 22. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB, Vanikar AV, Shah PR, Gumber MR, Patel HV, Godara SM, Munjappa BC, Sainaresh VV, Engineer DP, Jain SH, Modi PR, Shah VR, Trivedi VB, Trivedi HL.
    Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
    [Abstract] [Full Text] [Related]

  • 23. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 24. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J, Hatakeyama S, Wakai S, Omoto K, Okumi M, Tanabe K, Mieno M, Shirakawa H.
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [Abstract] [Full Text] [Related]

  • 25. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy.
    Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I.
    J Med Virol; 2013 May; 85(5):893-8. PubMed ID: 23508914
    [Abstract] [Full Text] [Related]

  • 26. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network.
    Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
    [Abstract] [Full Text] [Related]

  • 27. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 28. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
    Boucher A, Lord H, Collette S, Morin M, Dandavino R.
    Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
    [Abstract] [Full Text] [Related]

  • 29. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA, Kalpoe JS, van de Linde P, Vaessen N, Ringers J, Kroes AC, Roep BO, De Fijter JW.
    Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
    [Abstract] [Full Text] [Related]

  • 30. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis.
    Hammond SP, Martin ST, Roberts K, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR.
    Transpl Infect Dis; 2013 Apr; 15(2):163-70. PubMed ID: 23230972
    [Abstract] [Full Text] [Related]

  • 31. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A, Krok K, Cohen D, Blumberg E, Bloom RD.
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [Abstract] [Full Text] [Related]

  • 32. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.
    Jamal AJ, Husain S, Li Y, Famure O, Kim SJ.
    Transplantation; 2014 Mar 15; 97(5):569-75. PubMed ID: 24398852
    [Abstract] [Full Text] [Related]

  • 33. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
    da Cunha-Bang C, Sørensen SS, Iversen M, Sengeløv H, Hillingsø JG, Rasmussen A, Mortensen SA, Fox ZV, Kirkby NS, Christiansen CB, Lundgren JD.
    Scand J Infect Dis; 2011 May 15; 43(5):360-5. PubMed ID: 21306196
    [Abstract] [Full Text] [Related]

  • 34. Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.
    Werzowa J, Schwaiger B, Hecking M, Strassl R, Schmaldienst S, Böhmig GA, Genser B, Säemann MD.
    Clin Transplant; 2015 Dec 15; 29(12):1230-8. PubMed ID: 26458731
    [Abstract] [Full Text] [Related]

  • 35. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD.
    Transplantation; 2006 Apr 27; 81(8):1106-11. PubMed ID: 16641594
    [Abstract] [Full Text] [Related]

  • 36. Historical comparison of prophylactic ganciclovir for gastrointestinal cytomegalovirus infection in kidney transplant recipients.
    Kim HC, Hwang EA, Park SB, Kim HT, Cho WH.
    Transplant Proc; 2012 Apr 27; 44(3):710-2. PubMed ID: 22483474
    [Abstract] [Full Text] [Related]

  • 37. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C, Pérez-Romero P, Blanco-Lobo P, Benmarzouk-Hidalgo OJ, Sánchez M, Gentil MA, Bernal C, Sobrino JM, Rodríguez-Hernández MJ, Cordero E, Spanish Network for Research in Infectious Diseases (REIPI).
    Transpl Int; 2014 Oct 27; 27(10):1060-8. PubMed ID: 24964364
    [Abstract] [Full Text] [Related]

  • 38. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K, Basu A, Tan HP, Thai N, Khan A, Marcos A, Starzl TE, Shapiro R.
    Transplant Proc; 2004 Dec 27; 36(10):3107-12. PubMed ID: 15686707
    [Abstract] [Full Text] [Related]

  • 39. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný K, Treska V.
    J Clin Virol; 2006 Jun 27; 36(2):146-51. PubMed ID: 16531113
    [Abstract] [Full Text] [Related]

  • 40. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients.
    San Juan R, Yebra M, Lumbreras C, López-Medrano F, Lizasoain M, Meneu JC, Delgado J, Andrés A, Aguado JM.
    Clin Transplant; 2009 Jun 27; 23(5):666-71. PubMed ID: 19689451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.